Nasopharyngeal Synovial Sarcoma - An Oncological Surprise by Kannan, Ram Abhinav et al.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Corresponding author: Ram Abhinav Kannan; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore, India.
Cite this article as: Kannan RA, Koushik K, Kilara N, Gangoli A. Nasopharyngeal synovial sarcoma - An oncological surprise. Int J Cancer Ther Oncol 2014;
2(4):020412. DOI: 10.14319/ijcto.0204.12
Nasopharyngeal synovial sarcoma - An oncological surprise
1Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore, India
2Department of Medical Oncology, M S Ramaiah Medical College, Bangalore, India
3Department of Pathology, HCG Oncology, Bangalore, India
Received August 05, 2014; Revised October 04, 2014; Accepted October 05, 2014; Published Online October 09, 2014
Case Report
Abstract
Synovial sarcoma is a rare and aggressive high-grade neoplasm with poor prognosis. It is usually encountered in the lower ex-
tremities of young adults; only a few cases have been reported in the head and neck region. We report the fourth case of syno-
vial sarcoma of the nasopharynx, treated with neoadjuvant chemotherapy, complete surgical excision and adjuvant radiation
with extensive review of literature.
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Introduction
Synovial sarcoma is a rare malignant tumor that derives from
a mesenchymal precursor stem cell that is unrelated to ma-
ture synovial tissue. It is an aggressive high-grade neoplasm
with poor prognosis. It accounts for about 10% of all soft
tissue sarcomas and the most common location is the lower
extremities. Around 10% of them occur in the head and
neck.1, 2 The nasopharynx is an unusual site for this tumor.
Owing to the paucity of cases of synovial sarcoma in the
nasopharynx, information regarding appropriate therapy for
this tumor is limited. We report the fourth case of a synovial
sarcoma arising from the nasopharynx along with a review of
the available literature.
Case presentation
A 19-year-old male presented with complaints of nasal ob-
struction and intermittent headache that gradually pro-
gressed over 1 month. Flexible endoscopic examination re-
vealed a soft tissue mass in the left side of nasopharynx with
extension to oropharynx. Computed tomography scan (CT
scan) with intravenous contrast revealed an ill-defined mass
in the left side of nasopharynx measuring 2.5 × 3 × 3.5 cms
(Figure 1).
Biopsy of the tissue mass showed malignant spindle cell tu-
mour. Immunohistochemistry revealed tumor cells positive
for vimentin, EMA, Bcl-2 with focal expression of CK and
negative for SMA and S-100 consistent with the diagnosis of
monophasic synovial sarcoma.
FIG.1: CT scan showing asymmetric soft tissue thickening in the
lateral wall of nasopharynx.
[18]-Fluorodeoxyglucose PET-CT scan was done, which
showed an asymmetric soft tissue thickening in the lateral
wall of nasopharynx with extension to left lateral soft palate
extending up to left tonsil measuring 3.3 × 2.6 cms with no
significant metabolic activity. Patient underwent three cy-
cles of neoadjuvant ifosfamide and doxorubicin chemother-
apy followed by surgical excision of the tumor via oral cavity
under general anesthesia. The resected tumor measured 1.5 ×
1.5 cm with focal close posterior margin (0.3 cm). The histo-
pathological examination and immunohistochemistry was
consistent with pre-treatment diagnosis of monophasic syn-
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ovial sarcoma (Figure 2a, 2b, 2c, 2d). Reverse transcriptase
polymerase chain reaction (RT-PCR) for SYT-SSX fusion
transcript was negative. Further cytogenetic analysis re-
vealed no visible rearrangement of chromosome bands Xp 11
or 18q 11. Since the surgical margins were < 1 cm, patient
received postoperative local radiation to a dose of 60Gy in 30
fractions using volumetric arc therapy (VMAT).
FIG. 2(a): Spindle cells with hyperchromatic nuclei arranged in
fascicles and in interlacing pattern.
FIG. 2(b): Bcl-2 positivity.
FIG. 2(c): Vimentin Positivity.
FIG. 2(d): Epithelial Membrane Antigen positivity.
Discussion
Head and neck synovial sarcoma presents both diagnostic
and treatment challenges because of the limitations of
knowledge and experience for this neoplasm. Median age of
occurrence is in the third decade with a male preponderance
of 3:2.3 Of these, synovial sarcomas of the nasopharynx are
an extremely rare entity. Only three previous cases arising in
the nasopharynx have been described in the literature.4, 5, 6
There are two forms of synovial sarcoma; the biphasic and
monophasic. The biphasic type is the classic type that con-
tains epithelial and spindle-cell components in various pro-
portions, whereas the monophasic fibrous type contains only
spindle cells. The t(X;18) translocation is a specific marker of
synovial sarcomas. SYT-SSX1, SYT-SSX2, or the rarest
SYT-SSX4 gene fusion product is derived from t(x;18)
(p11.2;q11.2) and currently considered as a tumor-specific
genetic hallmark because it is present in more than 95% of
cases.5, 7 No visible rearrangement of chromosome bands is
seen in a small proportion of synovial sarcomas.8
The primary treatment of synovial sarcoma is a wide surgical
excision to obtain tumor-free margins. However, this cannot
always be accomplished in nasopharyngeal cases because of
the proximity of the tumor to vital structures.5 Tumors tend
to spread beyond their visible and palpable limits.9 Most
authors report that patients treated with surgery and adju-
vant radiotherapy had higher survival and lower recurrence
rates than did those treated with surgery alone.3 Also the
overall value of the postoperative RT in soft tissue sarcomas
has been found to be maximal in synovial sarcoma of the
head and neck.10 Lung is the most common site of metastases
(>90%).11 The value of chemotherapy in enhancing dis-
ease-free survival has not been firmly established. Lenoir et
al.12, reported a dramatic regression in tumor size in a
15-month-old patient with a retropharyngeal synovial sar-
coma after initial treatment with a combination of
Ifosfamide, Vincristine, and Actinomycin D. Post-operative
chemotherapy has also been advocated for prevention/delay
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of distant metastases although its role remains to be estab-
lished
Favorable prognostic indicators include an early diagnosis,
small tumor size (<5 cm), younger age (<20 yr), and a wide
surgical excision.13, 14, 15 Of these, tumor size is the single
most important prognostic determinant, as tumors of >10 cm
in diameter are associated with a poor prognosis.16 DNA
ploidy may also be an important prognostic factor, with an-
euploid tumors reported to diminish survival.17 Extensive
osteoid and bone formation in synovial sarcomas was found
to be associated with a favorable prognosis.18
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